Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on 1^st May 2022.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website. 

Spinal muscular atrophy

Onasemnogene abeparvovec (Zolgensma®) multiple strengths and forms determined by dosage and patients weight are now listed on the PBS for the treatment of spinal muscular atrophy. Authority applications for initial treatment can be made in writing.

Severe crohn disease & Moderate to severe ulcerative colitis

Adalimumab (Humira®) 80mg in 0.8 ml pre-filled syringe is a new and change to the formulation size for PBS listed for the treatment of severe crohn disease and moderate to severe ulcerative colitis. Authority applications for initial and continuing treatment can be made in writing.

Growth Hormone

There are some changes to the eligibility criteria for Somatropin listings on the PBS for paediatric growth hormone. Authority applications for all indications and treatment phasesinitial and continuing treatment can be made either in real time using the Online PBS Authorities system or in writing.

Progressive fibrosing interstitial lung disease

Nintedanib (Ofev®) is now listed on the PBS for the treatment of progressive fibrosing interstitial lung disease. Authority applications for initial and continuing treatment can be made in writing.

Progressive fibrosing interstitial lung disease

Nintedanib (Ofev®) is now listed on the PBS for the treatment of progressive fibrosing interstitial lung disease. Authority applications for initial and continuing treatment can be made in writing.

Uncontrolled severe eosinophilic, allergic asthma and severe asthma

The Grandfather clause for Duplimumab (Dupixent®) for the treatment of uncontrolled severe eosinophilic, allergic asthma and severe asthma has been removed.

Pulmonary arterial hypertension

The Grandfather clause for Selexipag (Uptravi®) for the treatment of pulmonary arterial hypertension has been removed.

Stage IV (metastatic) non-small cell lung cancer

The Grandfather clause for Osimertinib (Tagrissoi®) for the treatment of pulmonary arterial hypertension has been removed.

Castration resistant non-metastatic carcinoma of the prostate

Apalutamide (Erlyand®) 60 mg tablet is now listed on the PBS for the treatment of Castration resistant non-metastatic carcinoma of the prostate. Authority applications for initial, initial grandfather and continuing treatment can be made either in real time using the Online PBS Authorities system or by telephone.

Relapsed and/or refractory multiple myeloma

Elotuzuamab (Empliciti®) I.V. infusions 300 mg and 400 mg is now listed on the PBS for the treatment of relapsed and/or refractory multiple myeloma. Authority applications for initial and continuing treatment can be made either in real time using the Online PBS Authorities system or by telephone.

Eosinophilic oesophagitis

Budesonide (Jorveza®) 0.5 mg & 1 mg tablet is now listed on the PBS for the treatment of eosinophilic oesophagitis. Authority applications for initial and continuing treatment can be made either in real time using the Online PBS Authorities system or by telephone.

 

Breast cancer

Sacituzumab govitecan (Trodelvy®) 180 mg powder for injection is now listed on the PBS for treatment of breast cancer. Treatment is Authority Required (STREAMLINED).

Covid-19

Nirmatrevir & ritonavir (Paxlovid®) 150 mg nirmatrelvir tablet & 100 mg ritonavir tablet combination pack are now listed on the PBS for treatment of covid-19. Treatment is Authority Required (STREAMLINED).

1 May 2022 delisted PBS listings

There are no delisting’s for May 2022.

Selecting the correct restriction in the Online PBS Authorities system

Balance of Supply (BoS) restrictions are available through the Online PBS Authorities system. New questions and answers (Q&As) have been applied against BoS restrictions for multiple medicines listed on the PBS for multiple Authority Required (Written) programs to ensure prescribers are selecting the correct restriction and treatment phase to determine their patients eligibility. These Q&As will also ensure prescribers are using the correct authority submission channel for the required treatment phase to avoid post compliance activities.

To learn more about these updates, please contact Services Australia directly.

At Practice Managers Australia, we support Practice Managers in both staff recruitment and retention, and ensure that our service and advice is tailored to your specific goals to promote growth and flourishing.

Follow our LinkedIn and Facebook pages for more information.